Jane M. Love, Ph.D. is a partner in the New York office of Gibson, Dunn & Crutcher where she is a member of the Intellectual Property and Life Sciences Practice Groups. Her practice spans four areas: (1) patent litigation, (2) Patent Office trial proceedings including inter partes reviews (IPRs), (3) strategic patent prosecution advice and (4) patent diligence in transactions.
Dr. Love has extensive experience in pharmaceutical and biologics patent issues, including Abbreviated New Drug Application (ANDA) litigation, Biologics Price Competition and Innovation Act of 2009 (BPCIA) biosimilar litigation issues, and PTO Inter Partes Reviews under the America Invents Act (AIA). Dr. Love has coordinated global litigation of patents worldwide.
Dr. Love is experienced in a wide array of life sciences areas such as pharmaceuticals, biologics, biosimilars, antibodies, immunotherapies, genetics, vaccines, protein therapies, blood factors, medical devices, diagnostics, gene therapies, RNA therapies, bioinformatics and nanotechnology. She is a patent attorney registered to practice before the U.S. Patent and Trademark Office and has prosecuted hundreds of patent applications.
Dr. Love writes and speaks extensively on intellectual property issues. She is consistently named an "IP Star" by Managing IP. Dr. Love was named in Legal Media Group's Expert Guides 2017 Guide to the World's Leading Women in Business Law for Patents, a "Life Sciences Star" by LMG Life Sciences in 2014. She was named one of the "Top 250 Women in IP" by Managing IP in its four most recent lists and was named one of the IP attorneys in the "Top 50 Under 45" list by IP Law & Business in 2008.
Before joining Gibson Dunn, Dr. Love was the Co-Vice Chair of the Intellectual Property Department of Wilmer Hale and associated with that firm in New York since 2001. For seven years before that, Dr. Love practiced in an IP boutique law firm in New York.
Dr. Love received a J.D. from Fordham University School of Law. Before practicing law, Dr. Love conducted doctoral research at the University of Pennsylvania and Thomas Jefferson Medical School in Philadelphia and post-doctoral research at Cornell University Weill Medical College in New York City in molecular biology, pharmacology and cell and developmental biology. She served as a Captain in the U.S. Army Reserve Medical Service Corp from 1991 to 1997.
- Novartis Pharmaceuticals Corp.: Co-lead counsel in ANDA litigation against multiple generic defendants enforcing patents covering Gilenya®, the first oral treatment for multiple sclerosis.
- Novartis Pharmaceuticals Corp.: Lead counsel in inter partes review (IPR) defending patent covering Gilenya® against three petitioners before the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office.
- Novartis Pharmaceuticals Corp.: Co-lead counsel in ANDA litigation against more than 20 generic defendants enforcing several patents covering Reclast® and Zometa®, treatments for osteoporosis and cancer.
- Novartis Pharmaceuticals Corp.: Co-lead counsel in ANDA litigation against multiple generic defendants enforcing patents covering Exjade®, a medicine for treatment of iron overload resulting from blood transfusions.
- Confidential client: Advice related to Biologics Price Competition and Innovation Act of 2009 (BPCIA) and defense against biosimilar challenges.
- Abbott Laboratories: Co-lead counsel in patent litigation asserting patents directed to human antibodies directed against the cytokine IL-12 and methods to treat autoimmune diseases.
- Confidential client: International arbitration related to patents covering gene sequencing devices and methods.
- Alnylam, Inc.: Lead counsel in a patent interference before the Board of Patent Appeals and Interferences at the U.S. Patent and Trademark Office related to small interfering RNAs, siRNAs, used for the treatment of cancer.
- Japanese Foundation for Cancer Research: Co-lead counsel in patent interference before the Board of Patent Appeal and Interferences at the U.S. Patent and Trademark Office related to nucleic acids encoding interferon-beta, one of the first human proteins cloned.
- Cephalon, Inc.: ANDA litigation enforcing patents covering Provigil®, a drug used to aid in wakefulness.
- Hologic, Inc.: Lead counsel in a patent interference before the Board of Patent Appeals and Interferences at the U.S. Patent and Trademark Office related to breast biopsy devices.
- Columbia University: Patent interference before the Board of Patent Appeals and Interferences at U.S. Patent and Trademark Office related to antibodies directed to immune-related cytokine and methods of using antibodies to treat immune diseases.